中文

药明康德 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥12.44B+28.8%
Gross profit¥6.27B
Operating income¥5.61B
Net income¥4.67B+25.7%
Gross margin50.4%Net margin 37.6%
Revenue Q/Q-1.3%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥6.17B49.6%
R&D¥0.27B2.1%
SG&A¥0.89B7.2%
Tax & other¥0.94B7.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

合盛硅业海天味业华勤技术今世缘万泰生物豪威集团华友钴业瑞芯微兆易创新洛阳钼业德业股份东鹏饮料

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies